Boston Partners Raises Position in Phreesia, Inc. $PHR

Boston Partners boosted its holdings in Phreesia, Inc. (NYSE:PHR) by 165.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 130,060 shares of the company’s stock after purchasing an additional 81,006 shares during the period. Boston Partners owned approximately 0.22% of Phreesia worth $3,702,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PHR. Cubist Systematic Strategies LLC bought a new stake in Phreesia during the 1st quarter valued at $774,000. Farther Finance Advisors LLC increased its position in shares of Phreesia by 9,375.0% in the second quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock valued at $86,000 after acquiring an additional 3,000 shares during the period. Arcadia Investment Management Corp MI raised its stake in shares of Phreesia by 22.3% during the second quarter. Arcadia Investment Management Corp MI now owns 113,470 shares of the company’s stock valued at $3,229,000 after acquiring an additional 20,700 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Phreesia by 30.6% during the first quarter. Deutsche Bank AG now owns 74,857 shares of the company’s stock valued at $1,913,000 after acquiring an additional 17,560 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of Phreesia by 105.2% during the first quarter. Acadian Asset Management LLC now owns 225,317 shares of the company’s stock worth $5,754,000 after purchasing an additional 115,527 shares during the period. 92.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. JMP Securities boosted their price target on Phreesia from $30.00 to $34.00 and gave the company a “market outperform” rating in a report on Monday, September 8th. Raymond James Financial set a $33.00 price objective on Phreesia and gave the stock an “outperform” rating in a research report on Friday, September 5th. Truist Financial upped their target price on Phreesia from $35.00 to $36.00 and gave the company a “buy” rating in a report on Friday, September 5th. DA Davidson upgraded shares of Phreesia to a “strong-buy” rating in a report on Monday, September 8th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.71.

Insider Transactions at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,241 shares of the business’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $22.36, for a total value of $27,748.76. Following the sale, the general counsel directly owned 135,737 shares of the company’s stock, valued at approximately $3,035,079.32. The trade was a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Linetsky sold 2,059 shares of the firm’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $22.36, for a total value of $46,039.24. Following the transaction, the insider owned 171,829 shares of the company’s stock, valued at $3,842,096.44. The trade was a 1.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 26,174 shares of company stock worth $603,835. Company insiders own 5.50% of the company’s stock.

Phreesia Stock Down 0.2%

NYSE:PHR opened at $20.50 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. The firm’s 50-day moving average price is $22.45 and its 200-day moving average price is $25.46. The company has a market capitalization of $1.23 billion, a PE ratio of -48.80 and a beta of 0.74. Phreesia, Inc. has a 1-year low of $18.55 and a 1-year high of $32.76.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. The company had revenue of $117.26 million during the quarter, compared to analysts’ expectations of $116.39 million. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. Phreesia’s revenue was up 14.9% on a year-over-year basis. During the same period last year, the company posted ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. On average, equities analysts predict that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.